List view / Grid view
The approach proposed in the paper suggests how artificial intelligence (AI) and machine learning (ML) could enhance process efficiency and product quality during complex manufacturing.
The Phase II clinical trial is the first completed prospective trial for refractory meningiomas with a tumour growth rate of 15 percent or more over six months.
Find out what is on offer for pharma professionals working in analytical development and microbiology QC at the 12th PharmaLab Congress being held in Germany in 2024.
The detection method was designed for continuous culture monitoring of cell therapy products and required minimal sample preparation, research showed.
European Pharmaceutical Review’s latest Pharma Horizons report provides insight on key developments in pharmaceutical biologics for drug development, pharmaceutical manufacturing and quality control.
Limited funding and a lack of drugs targeting the root cause of sepsis are some of the current obstacles when addressing the disease burden, GlobalData says.
The expansion is planned to support production of Eli Lilly and Company’s medicines for diabetes, obesity and Alzheimer's and both sites will harness advanced technology and sustainability capabilities.
Sanofi’s novel manufacturing unit in France shortens production timelines and enables rapid changes in production capacities for medicines such as biologics and vaccines.
Some of the rare disease participants experienced fast and sustained improvement in their eyesight during the clinical trial, data shows.
The automated system “significantly improved process control”, resulting in greater productivity of a small-molecule drug substance.
The novel, environmentally-friendly synthesis strategy holds potential for manufacturing scale up, according to the research.
The multi-target biologic-focused agreement could enhance treatment convenience by improving subcutaneous administration options for patients.
The planned expansion is set to strengthen AstraZeneca’s capability to manufacture biologic medicines for patients globally.
The analysis technique offers “significant” advantages over traditional colony forming unit (CFU) counts, according to the paper.
The nonIP-RP-LC-MS method provides an “easy, reliable, and cost-effective” approach for bioanalysing oligonucleotide therapies.
